Groupe la Francaise’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$367K Sell
16,100
-2,073
-11% -$54.2K ﹤0.01% 365
2026
Q1
$476K Sell
18,173
-1,399
-7% -$37.2K 0.01% 318
2025
Q4
$449K Sell
19,572
-57,856
-75% -$1.46M 0.01% 312
2025
Q3
$1.62M Buy
77,428
+52,653
+213% +$1.3M 0.02% 265
2025
Q2
$598K Sell
24,775
-137,438
-85% -$3.21M 0.01% 289
2025
Q1
$3.97M Buy
162,213
+19,291
+13% +$505K 0.08% 153
2024
Q4
$2.3M Buy
+142,922
New +$3.88M 0.06% 175

Other funds holding PFE

Groupe la Francaise's PFE Position: Q2 2026 in Review

Groupe la Francaise reduced its Pfizer (PFE) stake by 11% in Q2 2026, selling an estimated $54.2K and leaving 16,100 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Groupe la Francaise first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.97M in Q1 2025. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Groupe la Francaise held 16,100 shares of Pfizer worth $367K as of Q2 2026.
  • Groupe la Francaise sold 2,073 Pfizer shares in Q2 2026, an estimated $54.2K.
  • Pfizer made up ﹤0.01% of Groupe la Francaise's portfolio in Q2 2026, its #365 holding.
  • Groupe la Francaise first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Groupe la Francaise's Pfizer position peaked at $3.97M in Q1 2025.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Groupe la Francaise's 13F filing for Q2 2026, filed 25 Aug 2026.